Funding Opportunity RFA-CA-23-041 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate sharing of complex single-cell level data with the cancer research community. The Human Tumor Atlas Network Data Coordinating Center (HTAN-DCC) will serve the dual role of network and data coordination. Administratively the HTAN-DCC will be responsible for meeting coordination, including planning and administration of monthly HTAN Steering Committee meetings, monthly HTAN working group meetings, and semi-annual HTAN face-to-face meetings. A focus on HTAN data and tool reusability through the development and deployment of community education resources will outweigh the need for creating additional data sharing infrastructure in the renewal period. Additionally, it is expected that the HTAN-DCC will remain a testbed for important interactions with the NCI Cancer Research Data Commons (CRDC) and will further drive development of CRDC resources required for sharing, interacting with, and integrating across highly multiplexed imaging datasets. The HTAN-DCC will also work closely with the CRDC to ensure all relevant data and metadata is transferred to the CRDC for long-term data sustainability. Just as they did in the first phase of HTAN, these important interactions will benefit a wide scientific community and have the potential to synergize with other NCI and NIH supported programs. A reduced budget request for the HTAN-DCC reflects reuse of infrastructure developed within the first phase of HTAN, while acknowledging that a significant number of nimble and responsive HTAN-DCC personnel are required for data wrangling, ingest, and sharing.

From £41,935, with benefits, subject to skills and experience: The Francis Crick Institute: This role will be pivotal in ensuring continuation of research on endogenous retroviruses in human cancer in the Kassiotis lab London (Central), London (Greater)

Funding Opportunity RFA-OD-24-001 from the NIH Guide for Grants and Contracts. To advance the goals of the NIH Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE) Initiative, this NIH Research Career Enhancement Award (K18) invites applications from experienced investigators in maternal morbidity and mortality research seeking to expand their research programs through the acquisition of new skills and knowledge in the area of intimate partner (and related) violence (IPV). The program will support research training and career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to integrate IPV and related violence constructs, theories, and/or interventions into their ongoing research efforts. Eligible candidates are independent investigators at any faculty rank or level.

Notice NOT-AG-23-056 from the NIH Guide for Grants and Contracts

Notice NOT-HD-23-026 from the NIH Guide for Grants and Contracts

Notice NOT-HL-23-097 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-179 from the NIH Guide for Grants and Contracts

Notice NOT-HD-23-021 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-23-039 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for Human Tumor Atlas (HTA) Research Centers, one of the three scientific components of the Human Tumor Atlas Network (HTAN) (NCI Human Tumor Atlas Network). HTAN is a collaborative research initiative for constructing 3-dimensional(3D) and dynamic atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments as they progress from precancerous lesions to advanced disease.Each HTA Research Center will construct one human precancer or advanced cancer atlas with an explicit focus on how evolving spatial relationships contribute to important transitions in cancer from tumor initiation to metastasis.The other two HTAN components are Precancer Atlas (PCA) Research Centers and a Data Coordinating Center (DCC). Each PCA Research Center will construct one 3D precancer atlas that comprehensively characterizes a premalignant lesion with an explicit focus on understanding the transition from a precancerous lesion to malignancy.The DCC will serve the dual role of network and data coordination. It will also be responsible for meeting coordination.Research Centers have three major areas of responsibility: (1) biospecimen acquisition, processing, and annotation, (2) molecular, cellular, and spatial characterization, and (3) data processing, analysis, modeling, and visualization.

Funding Opportunity RFA-CA-23-040 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for Precancer Atlas (PCA) Research Centers, one of the three scientific components of the Human Tumor Atlas Network (HTAN) (https://humantumoratlas.org/).HTAN is a collaborative research initiative for constructing 3-dimensional(3D) and dynamic atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments as they progress from precancerous lesions to advanced disease.Each PCA Research Center will construct one 3D precancer atlas that comprehensively characterizes a pre-malignant lesion with an explicit focus on understanding the transition from a precancerous lesion to malignancy. The other two HTAN components are Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC).Each HTA Research Center will conduct research to develop onespatial tumor atlas at single-cell resolution driven by specific topics in cancer biology across the continuum from cancer initiation to metastasis.

Notice NOT-AG-23-058 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-222 from the NIH Guide for Grants and Contracts. The purpose of the Advancing Research Careers (ARC) Predoctoral to Postdoctoral Transition Award to Promote Diversity (F99/K00) program is to support promising, late-stage graduate students from diverse backgrounds (e.g., see Notice of NIHs Interest in Diversity) to transition into and succeed in mentored postdoctoral research positions. It is anticipated that successful completion of this phased award program will position ARC scholars to advance in impactful careers in the biomedical research workforce that typically require postdoctoral training (e.g., academic research and teaching at a range of institution types, industry or government research). This two-phase award will provide support for late-stage graduate students pursuing research related to the mission areas of participating NIH Institutes, Centers, and Offices (ICOs) to facilitate the completion of doctoral dissertation projects and research training (F99 phase), and to transition into and succeed in postdoctoral biomedical research and career development opportunities (K00 phase). ARC F99 fellows/K00 scholars will be part of organized cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by ARC Institutionally-Focused Research Education Award to Promote Diversity (UE5) recipients.

Funding Opportunity PAR-23-221 from the NIH Guide for Grants and Contracts. The overarching goal of the ARC UE5 program is to provide ARC F99 fellows/K00 scholars with professional skills and the appropriate mentoring and networks to allow them to transition into and succeed in postdoctoral research and career development opportunities, positioning them to advance in impactful careers in the biomedical research workforce that typically require postdoctoral training (e.g., academic research and teaching at a range of institution types, industry or government research). To accomplish the stated over-arching goal, this Notice of Funding Opportunity will support evidence-informed educational activities with a primary focus on courses for skills development and mentoring activities.

Notice NOT-HD-23-033 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-039 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-005 from the NIH Guide for Grants and Contracts

Notice NOT-HL-23-091 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-192 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-24-032 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage clinical research that will identify and validate novel targets for non-invasive brain stimulation (NIBS) and SUD-relevant neurobiological, cognitive, and behavioral responses to NIBS that precede clinical outcomes like reduced craving or drug use. This NOFO uses an R01 activity code to support applications that propose mechanistic studies designed to understand a behavior or biological process, the pathophysiology of a disease, or the mechanism of action of an intervention. In addition, applications must meet the NIH definition of a clinical trial. NIH defines a clinical trial as A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. (NOT-OD-15-015) This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Funding Opportunity RFA-DA-24-033 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage clinical research that will identify and validate novel targets for non-invasive brain stimulation (NIBS) and SUD-relevant neurobiological, cognitive, and behavioral responses to NIBS that precede clinical outcomes like reduced craving or drug use. Applications are expected to be exploratory and developmental in nature. As such, these studies may involve considerable risk of failure but may lead to a breakthrough in a particular area that could have a major impact on SUD research involving NIBS. This NOFO uses a R61/R33 Phased Innovation award activity code to support applications that propose mechanistic studies designed to understand a behavior or biological process, the pathophysiology of a disease, or the mechanism of action of an intervention. In addition, applications must meet the NIH definition of a clinical trial. NIH defines a clinical trial as A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. (NOT-OD-15-015)